Icahn Sues Amylin For Docs On Rebuffed $3.5B Bristol Bid

Law360, Wilmington (April 12, 2012, 4:24 PM EDT) -- Activist investor Carl Icahn stepped up his pressure Thursday on Amylin Pharmaceuticals Inc. over the company's alleged rejection of a $3.5 billion offer from Bristol-Myers Squibb Co., filing suit to force the drugmaker to open its books and records to shareholders.

On Wednesday, Amylin “flatly refused” a so-called Section 220 demand to voluntarily turn over records related to Bristol Myers’ February offer — along with documents on a subsequent grant of stock options and a public offering allegedly priced well below that bid, Icahn Partners LP...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.